December 12, 2012: by Bill Sardi
MicroRNA studies conducted at the National Institutes of Health reveal one particular brand of resveratrol-based pill, Longevinex®, exhibits a distinctive gene activity pattern apart from plain resveratrol. In particular, Longevinex strongly inhibits production of gene proteins produced when tissues are deprived of oxygen and subsequently develop new abnormal blood vessels in an attempt to deliver O2 to tissues.
In the study published in PLoS ONE, just two microRNA represented over 90% of Longevinex’ broad gene activity. (Micro RNA are small RNA molecules that regulate gene activity.)
When diseased tissues are subjected to infection, inflammation or malignancy, an oxygen-poor state often occurs. Then, in response to this oxygen-less state, what biologists call hypoxia (hi-pox-ee-uh), new blood vessels form to deliver oxygen. This new blood vessel formation is what biologists called angiogenesis (an-gee-oh-jen-ess-iss).
This destructive process is seen at the back of the eye in cases of diabetes (diabetic retinopathy) and in wet macular degeneration, a disease that affects the visual center (macula) of the eyes. New abnormal blood vessels also form to feed tumors with oxygen and nutrients.
The idea of blocking the development of abnormal blood vessels was first suggested by Dr. Judah Folkman who worked tirelessly to develop anti-angiogenic drugs to treat cancer.
The state of hypoxia is induced by microRNA-539 that controls the HIF1 gene (hypoxia inducing factor gene). In turn, this triggers microRNA-20b that activates what is known as the vascular endothelial growth factor (VEGF) gene. VEGF weakens the walls of surrounding blood vessels to facilitate development of new arterial tributaries to deliver oxygen.
There are monoclonal antibody drugs that attempt to completely block VEGF. They have not been very successful in controlling tumor growth but are commonly used with success to cause invasive new blood vessels to temporarily recede from the back of the eyes.
In a small number of cases, Longevinex® has been shown to recede new blood vessels at the back of human eyes when anti-VEGF drugs failed. This discovery suggests this nutriceutical combination of six natural molecules works synergistically to produce a profound and unprecedented biological effect that has not been duplicated with any other dietary supplements.
The scientific hoopla over resveratrol is not transferable to all of the 350 branded resveratrol dietary supplements. The unique biological action of Longevinex® suggests it stands apart from other nutriceuticals. Longevinex® has petitioned the Food & Drug Administration for permission to proceed with human studies among patients with wet macular degeneration.
While it cannot be said that Longevinex® treats, prevents or cures any disease, Longevinex® has exhibited unparalleled biological activity.